Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/s41434-020-00204-y http://scihub22266oqcxt.onion/10.1038/s41434-020-00204-y 33093657!7580817!33093657     free     free     free Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\33093657.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Gene+Ther 2021 ; 28 (3-4): 117-129 Nephropedia Template TP {{tp|p=33093657|t=2021. Self-amplifying RNA vaccines for infectious diseases |pdf=|usr=}}{{33093657}} gab.com Text Self-amplifying RNA vaccines for infectious diseases JO: Gene Ther http://www.kidney.de/pget.php?&tw=1&pmid=33093657 #FOAvip Vaccinology is shifting toward synthetic RNA platforms which allow for rapid, scalable, and cell-free manufacturing of prophylactic and therapeutic vaccines. The simple development pipeline is based on in vitro transcription of antigen-encoding sequences or immunotherapies as synthetic RNA transcripts, which are then formulated for delivery. This approach may enable a quicker response to emerging disease outbreaks, as is evident from the swift pursuit of RNA vaccine candidates for the global SARS-CoV-2 pandemic. Both conventional and self-amplifying RNAs have shown protective immunization in preclinical studies against multiple infectious diseases including influenza, RSV, Rabies, Ebola, and HIV-1. Self-amplifying RNAs have shown enhanced antigen expression at lower doses compared to conventional mRNA, suggesting this technology may improve immunization. This review will explore how self-amplifying RNAs are emerging as important vaccine candidates for infectious diseases, the advantages of synthetic manufacturing approaches, and their potential for preventing and treating chronic infections. Twit Text FOAVip Self-amplifying RNA vaccines for infectious diseases ????Gene Ther http://www.kidney.de/pget.php?&tw=1&pmid=33093657 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33093657 #FOAvip English Wikipedia <ref>{{Cite pmid|33093657}}</ref> Self-amplifying RNA vaccines for infectious diseases #MMPMID33093657 Bloom K; van den Berg F; Arbuthnot P Gene Ther 2021[Apr]; 28 (3-4): 117-129 PMID33093657show ga Vaccinology is shifting toward synthetic RNA platforms which allow for rapid, scalable, and cell-free manufacturing of prophylactic and therapeutic vaccines. The simple development pipeline is based on in vitro transcription of antigen-encoding sequences or immunotherapies as synthetic RNA transcripts, which are then formulated for delivery. This approach may enable a quicker response to emerging disease outbreaks, as is evident from the swift pursuit of RNA vaccine candidates for the global SARS-CoV-2 pandemic. Both conventional and self-amplifying RNAs have shown protective immunization in preclinical studies against multiple infectious diseases including influenza, RSV, Rabies, Ebola, and HIV-1. Self-amplifying RNAs have shown enhanced antigen expression at lower doses compared to conventional mRNA, suggesting this technology may improve immunization. This review will explore how self-amplifying RNAs are emerging as important vaccine candidates for infectious diseases, the advantages of synthetic manufacturing approaches, and their potential for preventing and treating chronic infections. |*Vaccination[MESH] |COVID-19 Vaccines/genetics/*immunology/therapeutic use[MESH] |COVID-19/epidemiology/genetics/*immunology/*prevention & control[MESH] |Humans[MESH] |RNA, Viral/genetics/*immunology/therapeutic use[MESH]Self-amplifying RNA vaccines for infectious diseases (epmc).pdf DeepDyve Pubget Overpricing